Monday, July 11, 2022

Ortho Regenerative Technologies Inc. (ORTIF)
Heal Better; Initiating Coverage with an Outperform Rating

Gregory Aurand, Senior Research Analyst, Healthcare Services & Medical Devices, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Unmet large market needs. Ortho Regenerative Technologies Inc. (Ortho RTI) is advancing its RESTORE regenerative medicine platform in rotator cuff tears and meniscus tears to improve healing. Rotator cuff and meniscus tears have high failure rates due to insufficient healing and tissue degeneration. For these two indications, Ortho RTI has a $1.8 billion US market opportunity. Globally, the market opportunity more than doubles. Additional future applications expand the opportunity further.

Safe and easy to produce. The proprietary RESTORE platform is a biopolymer matrix technology combining readily available chitosan, derived principally in shellfish, with autologous platelet-rich plasma (PRP). Using the patient’s own plasma substantially improves the safety profile while the chitosan provides site “stickiness”.

…

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.